| References |
|
|
Acar JR,
Courvalin P and
Chabbert YA
(1970)
Methicillin-resistant staphylococcemia: bacteriological failure of treatment with cephalosporins.
Antimicrobial Agents and Chemotherapy
10: 280–285.
|
|
|
Caputo GM,
Archer GL,
Calderwood SB,
DiNubile MJ and
Karchmer AW
(1987)
Native valve endocarditis due to coagulase-negative staphylococci. Clinical and microbiologic features.
American Journal of Medicine
83: 619–625.
|
|
|
Centers for Disease Prevention and Control
(1997)
Staphylococcus aureus with reduced susceptibility to vancomycin – United States.
MMWR
46: 765–766.
|
|
|
other
Centers for Disease Prevention and Control
(2002)
Vancomycin-resistant Staphylococcus aureus– Pennsylvania.
MMWR. Oct 11th 2002
p. 902.
|
|
|
Cercenado E,
Garcia-Leoni ME,
Diaz MD et al.
(1996)
Emergence of teicoplanin-resistant coagulase-negative staphylococci.
Journal of Clinical Microbiology
34: 1765–1781.
|
|
|
Chambers HF
(1997)
Methicillin resistance in staphylococci: molecular and biochemical basis and clinical implications.
Clinical Microbiology Reviews
10: 781–791.
|
|
|
Combined Working Party
(1998)
Revised guidelines for the control of methicillin-resistant Staphylococcus aureus infection in hospitals.
Journal of Hospital Infection
39: 253–290.
|
|
|
Cosgrove S,
Sakoulas G,
Peremcevitch EN et al.
(2003)
Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureusbacteraemia: a meta-analysis.
Clinical Infectious Diseases
36: 53–59.
|
|
|
Daum TE,
Schaberg DR,
Terpenning MS,
Sottile WA and
Kauffman CA
(1990)
Increasing resistance of Staphylococcus aureus to ciprofloxacin.
Antimicrobial Agents and Chemotherapy
34: 1862–1863.
|
|
|
de Gorgolas M,
Aviles P,
Verdejo C and
Fernandez Guerrero ML
(1995)
Treatment of experimental endocarditis due to methicillin-susceptible or methicillin-resistant Staphylococcus aureus with trimethoprim-sulfamethoxazole and antibiotics that inhibit cell wall synthesis.
Antimicrobial Agents and Chemotherapy
39: 953–957.
|
|
|
Engemann JJ,
Carmeli Y,
Cosgrove S et al.
(2003)
Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection.
Clinical Infectious Diseases
36: 592–598.
|
|
|
Enright MC,
Robinson DA,
Randle G et al.
(2002)
The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA).
Proceedings of the National Academy of Sciences of the USA
99: 7687–7692.
|
|
|
French G
(2003)
Safety and tolerability of linezolid.
Journal of Antimicrobial Chemotherapy
51(suppl. ii): 45–53.
|
|
|
ePath
Gemmell CG,
Edwards DI,
Fraise AP et al. for the BSAC/HIS/ICNA MRSA Working Party. Guidelines for the prophylaxis and treatment of meticillin (methicillin)-resistant Staphylococcus aureus (MRSA) infections in the United Kingdom. Draft for consultation 1-3-05. http://www.his.org.uk/_db/_documents/MRSA_treatment_consultation.pdf.
|
|
|
Hackbarth CJ and
Chambers HF
(1989)
Methicillin-resistant staphylococci: genetics and mechanisms of resistance.
Antimicrobial Agents and Chemotherapy
33: 991–994.
|
|
|
Hiramatsu K,
Hanaki H,
Ino T et al.
(1997)
Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.
Journal of Antimicrobial Chemotherapy
40: 135–136.
|
|
|
Hospital Infection Control Practices Advisory Committee
(1995)
Recommendations for preventing the spread of vancomycin-resistance.
Infection Control and Hospital Epidemiology
16: 105–113.
[Erratum: Infection Control and Hospital Epidemiology 16: 498.].
|
|
|
Johnson AP and
Livermore DM
(1999)
Quinupristin/dalfopristin, a new addition to the antimicrobial arsenal.
Lancet
354: 2012–2013.
|
|
|
Kaplan SL,
Mason EO Jr. and
Feigin RD
(1982)
Clindamycin versus nafcillin or methicillin in the treatment of Staphylococcus aureus osteomyelitis in children.
Southern Medical Journal
75: 138–142.
|
|
|
Karchmer AW
(1988)
Antibiotic therapy of nonenterococcal streptococcal and staphylococcal endocarditis: current regimes and some future considerations.
Journal of Antimicrobial Chemotherapy
21(suppl. C): 91.
|
|
|
Kirby WMM,
Perry DM and
Bauer AW
(1960)
Treatment of staphylococcal septicemia with vancomycin. Report of thirty-three cases.
New England Journal of Medicine
262: 49.
|
|
|
Korzeniowski O and
Sande MA
(1982)
The National Collaborative Endocarditis Study Group. Combination antimicrobial therapy for Staphylococcus aureus endocarditis for patients addicted to parental drugs and in nonaddicts.
Annals of Internal Medicine
97: 496.
|
|
|
Leclerq R and
Courvalin P
(1997)
Resistance to glycopeptides in enterococci.
Clinical Infectious Diseases
24: 545–556.
|
|
|
Livermore DM
(2003)
Linezolid in vitro: mechanism and antibacterial spectrum.
Journal of Antimicrobial Chemotherapy
51(Suppl. ii): 9–16.
|
|
|
Markowitz N,
Quinn EL and
Saravolatz LD
(1992)
Trimethoprim-sulphamethoxazole compared with vancomycin for the treatment of Staphylococcus aureus infection.
Annals of Internal Medicine
117: 390–398.
|
|
|
Massanari RM and
Donta ST
(1978)
The efficacy of rifampicin as adjunctive therapy in selected cases of staphylococcal endocarditis.
Chest
73: 375–377.
|
|
|
May J,
Shannon K,
King A and
French GL
(1998)
Glycopeptide tolerance in Staphylococcus aureus.
Journal of Antimicrobial Chemotherapy
42: 189–197.
|
|
|
Nichols RL,
Graham DR,
Barriere SL et al.
(1999)
Treatment of hospitalized patients with complicated gram-positive skin and skin structure infections: two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin.
Journal of Antimicrobial Chemotherapy
44: 263–273.
|
|
|
Noble WC,
Virani Z and
Cree RGA
(1992)
Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus.
FEMS Microbiology Letters
93: 195–198.
|
|
|
Patrick CC,
Kaplan SL,
Baker CJ,
Parisi JT and
Mason EO Jr
(1989)
Persistent bacteremia due to coagulase-negative staphylococci in low birth weight neonates.
Pediatrics
84: 977–985.
|
|
|
Protier H
(1990)
A multicentre, open, clinical trial of a new intravenous formulation of fusidic acid in severe staphylococcal infection.
Journal of Antimicrobial Chemotherapy
25(suppl. B): 39–44.
|
|
|
Shanson DC
(1981)
Antibiotic resistance in Staphylococcus aureus.
Journal of Hospital Infection
2: 11–36.
|
|
|
Shanson DC
(1990)
Clinical relevance of resistance to fusidic acid in Staphylococcus aureus.
Journal of Antimicrobial Chemotherapy
25(suppl. B): 15–21.
|
|
|
Speller DCE,
Johnson AP,
James D et al.
(1997)
Resistance to methicillin and other antibiotics in isolates of Staphylococcus aureus from blood and cerebrospinal fluid, England and Wales, 1989-95.
Lancet
350: 323–325.
|
|
|
Tamer MA and
Bray JD
(1986)
Trimethoprim-sulfamethoxazole treatment of multiantibiotic-resistant staphylococcal endocarditis and meningitis.
Clinical Pediatrics
21: 125–126.
|
|
|
Teare L,
Cookson B,
French G et al.
(1999)
Hand washing. A modest measure with big effects.
British Medical Journal
318: 686.
|
|
|
Van der Auwera P,
Klastersky J,
Thys JP et al.
(1985)
Double-blind, placebo-controlled study of oxacillin combined with rifampicin in the treatment of staphylococcal infections.
Antimicrobial Agents and Chemotherapy
28: 467.
|
|
|
Wilcox MH
(2003)
Efficacy of linezolid versus comparator therapies in Gram-positive infections.
Journal of Antimicrobial Chemotherapy
51(Suppl. ii): 27–35.
|
|
|
Wilson AP,
Gruneberg RN,
Treasure T and
Sturridge MF
(1988)
Staphylococcus epidermidis as a cause of postoperative wound infection after cardiac surgery: assessment of pathogenicity by a wound-scoring method.
British Journal of Surgery
75: 168–170.
|
|
|
book
Wilson APR and
Gruneberg RN
(1997)
Teicoplanin: The First Decade.
London: The Medicine Group.
|
| Further Reading |
|
|
book
Cohen J
(1997)
"Septicaemia".
In: O'Grady F,
Lambert HP,
Finch RG and
Greenwood D (eds)
Antibiotic and Chemotherapy, 7th ed.,
pp. 578–593.
New York: Churchill Livingstone.
|
|
|
Elliott TSJ
(1988)
Intravascular-device infections.
Journal of Medical Microbiology
27: 167–167.
|
|
|
book
Kucers A,
Hoy JF,
Lindsay GM and
Crowe SM
(1997)
The Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal and Antiviral Drugs, 5th edn.
Hodder Arnold Publications, 1997.
|
|
|
Michel M and
Gutmann L
(1997)
Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: therapeutic realities and possibilities.
Lancet
349: 1901–1906.
|
|
|
Mulligan ME,
Murray-Leisure KA,
Ribner BS et al.
(1993)
Methicillin-resistant Staphylococcus aureus: a consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management.
American Journal of Medicine
94: 313–328.
|
|
|
Rupp ME and
Archer GL
(1994)
Coagulase-negative staphylococci: pathogens associated with medical progress.
Clinical Infectious Diseases
19: 231–243.
|
